- Home
- HEPS vs XNCR Comparison
HEPS vs XNCR Comparison
Compare HEPS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | XNCR |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.4M | 928.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HEPS | XNCR |
|---|---|---|
| Price | $2.82 | $13.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.07 | ★ $22.78 |
| AVG Volume (30 Days) | 229.0K | ★ 707.0K |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,504,533,586.00 | $150,132,000.00 |
| Revenue This Year | $41.69 | $18.68 |
| Revenue Next Year | $29.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.77 | 38.16 |
| 52 Week Low | $2.15 | $6.92 |
| 52 Week High | $3.85 | $21.00 |
Technical Indicators
Market Signals| Indicator | HEPS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 39.46 |
| Support Level | $2.72 | $12.41 |
| Resistance Level | $2.85 | $13.75 |
| Average True Range (ATR) | 0.10 | 0.77 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 82.46 | 21.74 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.